Artivion, Inc. (NYSE:AORT) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Artivion, Inc. (NYSE:AORT) has received an average rating of “Moderate Buy” from the eight research firms that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating and seven have issued a buy rating on the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $44.1667.

A number of equities research analysts recently weighed in on AORT shares. Citizens Jmp dropped their price target on Artivion from $53.00 to $48.00 and set a “market outperform” rating for the company in a report on Friday, May 8th. Stifel Nicolaus set a $45.00 price target on shares of Artivion in a research report on Monday, June 1st. Weiss Ratings lowered shares of Artivion from a “hold (c-)” rating to a “sell (d+)” rating in a report on Monday, June 8th. Needham & Company LLC lowered their price objective on shares of Artivion from $58.00 to $44.00 and set a “buy” rating for the company in a research report on Friday, May 8th. Finally, Wall Street Zen cut shares of Artivion from a “buy” rating to a “hold” rating in a research report on Saturday, April 25th.

Artivion Stock Performance

NYSE:AORT opened at $23.91 on Monday. Artivion has a 1 year low of $19.16 and a 1 year high of $48.25. The firm has a 50 day moving average of $24.60 and a 200-day moving average of $34.52. The company has a current ratio of 3.86, a quick ratio of 2.80 and a debt-to-equity ratio of 0.48. The stock has a market capitalization of $1.16 billion, a P/E ratio of 99.63 and a beta of 1.26.

Insider Transactions at Artivion

In other news, SVP Andrew M. Green sold 44,001 shares of the firm’s stock in a transaction on Thursday, June 11th. The stock was sold at an average price of $20.70, for a total value of $910,820.70. Following the transaction, the senior vice president directly owned 60,259 shares in the company, valued at $1,247,361.30. This trade represents a 42.20% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 6.30% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Royal Bank of Canada increased its stake in Artivion by 107.0% in the first quarter. Royal Bank of Canada now owns 38,707 shares of the company’s stock valued at $952,000 after purchasing an additional 20,010 shares in the last quarter. AQR Capital Management LLC boosted its position in shares of Artivion by 8.8% during the first quarter. AQR Capital Management LLC now owns 35,053 shares of the company’s stock worth $862,000 after purchasing an additional 2,823 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Artivion by 4.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,591 shares of the company’s stock valued at $580,000 after buying an additional 1,032 shares during the period. Creative Planning grew its holdings in shares of Artivion by 5.6% in the 2nd quarter. Creative Planning now owns 14,272 shares of the company’s stock valued at $444,000 after buying an additional 753 shares during the period. Finally, Invesco Ltd. increased its position in shares of Artivion by 40.8% in the 2nd quarter. Invesco Ltd. now owns 481,026 shares of the company’s stock valued at $14,960,000 after buying an additional 139,370 shares in the last quarter. Institutional investors own 86.37% of the company’s stock.

Artivion Company Profile

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.